Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

midostaurin

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Multi-tyrosine kinase inhibitor

Related drugs:

‹

›

FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2
FLT3 mutation	Leukemia	FLT3 mutation	Leukemia	midostaurin Sensitive: B - Late Trials midostaurin Sensitive : B	midostaurin Sensitive: B - Late Trials midostaurin Sensitive : B
FLT3 D835	Acute Myelogenous Leukemia	FLT3 D835	Acute Myelogenous Leukemia	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2
FLT3 D835Y	Acute Myelogenous Leukemia	FLT3 D835Y	Acute Myelogenous Leukemia	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2
FLT3 I836	Acute Myelogenous Leukemia	FLT3 I836	Acute Myelogenous Leukemia	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2	midostaurin Sensitive: C2 – Inclusion Criteria midostaurin Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin Sensitive: C2 – Inclusion Criteria cytarabine + midostaurin Sensitive : C2	cytarabine + midostaurin Sensitive: C2 – Inclusion Criteria cytarabine + midostaurin Sensitive : C2
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3
KRAS mutation	Acute Myelogenous Leukemia	KRAS mutation	Acute Myelogenous Leukemia	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3	venetoclax + midostaurin Resistant: C3 – Early Trials venetoclax + midostaurin Resistant : C3